IE 11 is not supported. For an optimal experience visit our site on another browser.

Lithera Announces Notice of Allowance for a Key Patent Application for LIPO-102, a Novel Treatment for Localized Fat Reduction

SAN DIEGO, Oct. 12, 2010 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application broadly covering compositions and methods of use associated with LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction. Once issued, this patent will afford the company market exclusivity for LIPO-102 into 2028. This news follows Lithera's recent announcement of positive results from a Phase II clinical trial of LIPO-102 showing dose- and time-related reductions in mean abdominal circumference and volume.
/ Source: GlobeNewswire

SAN DIEGO, Oct. 12, 2010 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application broadly covering compositions and methods of use associated with LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction. Once issued, this patent will afford the company market exclusivity for LIPO-102 into 2028. This news follows Lithera's recent announcement of positive results from a Phase II clinical trial of LIPO-102 showing dose- and time-related reductions in mean abdominal circumference and volume.

About LIPO-102

LIPO-102 is being developed as a first-in-class injectable drug product designed to produce local, selective fat tissue reduction ( pharmaceutical lipoplasty ). Using FDA-registered drugs approved for use in other indications, LIPO-102 targets and stimulates natural fat tissue metabolism to achieve non-ablative, non-surgical fat tissue reduction in specific locations.  LIPO-102 is currently under development for the treatment of symptomatic exophthalmos (protrusion of the eye from the orbit) associated with thyroid-related eye disease (the thyroid condition is also known as Graves' Disease ) and the reduction of abdominal adiposity.

About

Lithera is a clinical stage company developing pharmaceutical and biomedical products addressing both medical and lifestyle indications in ophthalmology and aesthetic medicine.  Our lead product candidate (LIPO-102) is a novel injectable pharmaceutical product designed to produce local, selective fat tissue reduction (pharmaceutical lipoplasty).  Founded in 2007, the Company has assembled an exceptional team of senior executives, employees and advisors and has been financed by top-tier venture capital firms.  For more information on Lithera, Inc., please visit .

The Lithera, Inc. logo is available at

Lithera, LIPO-102 and the Lithera logo are trademarks or registered trademarks of Lithera, Inc. Other names and brands may be claimed as the property of others.

CONTACT: Lithera, Inc. Kenneth W. Locke, Ph.D., Chief Scientific Officer 858-750-1008 klocke@lithera.com 9191 Towne Centre Drive San Diego, CA 92122